

## FIGURE 1A


RMA vs RMAS +/- IFN, VSV




# FIGURE 1B


CMT64 +/- IFN, VSV







CMT 64 +/- VSV; Superinfection with Vac, or Vacb2









#### Dose Response





The state of the s







CMT.64 Transfectants +/- VSV











CMT 64 Transfectants +/- VSV




TAP 1 versus TAP 2 CMT 64 Transfectants +/- VSV



all the state of t


A Section of the state of the section of the sectio

CMT 64 Transfectants +/- VSV




E:T

#### CTL Response to Influenza




#### CTL Response to Influenza



and the state of t

#### CTL Response to Influenza



THE REAL PROPERTY OF THE PARTY OF THE PARTY

The state of the s

#### CTL Response to HSV-1







FIGURE 20







В 100 -VSV % Lysis 80 60 -- VV-NP-6 40 —**—** W-pJS5 20 ---- PBS 0 1 10 3 30 Effector:Target

A




В






 $\mathbf{B}$ 


	VV-NP	VV-NP + VV-hTAP12		
VSV pCTL	1/78,000	1/16,000		





Target RMA + 25µM VSV-Np peptide





T:E Ratio

















FIGURE 31





## FIGURE 32A







# TAP1 enhanced the presentation of VSV-NP by B16 cells










# TAP1 enhanced the presentation of TRP-2 by B16 cells





**Treatment** 





Α

Tumor	one month		two months		Ratiob	
	CD4%s	CD8%	CD4%	CD8%	CD4	CD8
CMT.neo	0 54	041				
CMT.1-1	1.02	0 87			1.9	2.1
CMT.1-4			1 07	1 20	2.0	29
CMT 1-10	4 19	2.94			7.8	7.2
CMT2-1	0 24	0.23			04	0.6
CMT2-10	0 12	0 66			0.2	16

